Discontinued — last reported Q4 '25
EMEA — Net Sales
Boston Scientific EMEA — Net Sales remained flat by 0.0% to $862.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.9%, from $807.00M to $862.75M. Over 4 years (FY 2021 to FY 2025), EMEA — Net Sales shows an upward trend with a 8.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market expansion, strong product adoption, or favorable pricing power in the region, while a decrease may signal competitive pressure, regulatory hurdles, or economic headwinds in these markets.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and related services within the Euro...
Peer comparison
Comparable to regional revenue reporting by other global medical device manufacturers, often benchmarked against regional GDP growth and healthcare spending trends.
bsx_segment_europe_middle_east_and_africa_net_salesHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $2.52B | $2.53B | $2.86B | $3.23B | $3.45B |
| YoY Change | — | +0.3% | +13.1% | +13.0% | +6.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's emea — net sales?
- Boston Scientific (BSX) reported emea — net sales of $862.75M in Q4 2025.
- How has Boston Scientific's emea — net sales changed year-over-year?
- Boston Scientific's emea — net sales increased by 6.9% year-over-year, from $807.00M to $862.75M.
- What is the long-term trend for Boston Scientific's emea — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's emea — net sales has grown at a 8.2% compound annual growth rate (CAGR), from $2.52B to $3.45B.
- What does emea — net sales mean?
- The total revenue earned from products sold in the Europe, Middle East, and Africa region.